Mouse models to assess the efficacy of non-typhoidal Salmonella vaccines: revisiting the role of host innate susceptibility and routes of challenge.
about
Intranasal vaccination in mice with an attenuated Salmonella enterica Serovar 908htr A expressing Cp15 of Cryptosporidium: impact of malnutrition with preservation of cytokine secretion.Immunity to intestinal pathogens: lessons learned from SalmonellaLive attenuated S. Typhimurium vaccine with improved safety in immuno-compromised mice.Why the development of effective typhoid control measures requires the use of human challenge studies.Sustained protection in mice immunized with fractional doses of Salmonella Enteritidis core and O polysaccharide-flagellin glycoconjugates.Invasive Salmonella Typhimurium ST313 with naturally attenuated flagellin elicits reduced inflammation and replicates within macrophages.Evaluation of the live vaccine efficacy of virulence plasmid-cured, and phoP- or aroA-deficient Salmonella enterica serovar Typhimurium in mice.Salmonella enterica serovar enteritidis core O polysaccharide conjugated to H:g,m flagellin as a candidate vaccine for protection against invasive infection with S. enteritidis.Identifying an immune signature against invasive SalmonellaCombination vaccines against diarrheal diseases.Functional Activity of Antibodies Directed towards Flagellin Proteins of Non-Typhoidal Salmonella.Evaluation of a Salmonella Strain Lacking the Secondary Messenger C-di-GMP and RpoS as a Live Oral VaccineA Highly Effective Component Vaccine against Nontyphoidal Salmonella enterica Infections.Refined live attenuated Salmonella enterica serovar Typhimurium and Enteritidis vaccines mediate homologous and heterologous serogroup protection in mice.New technologies in developing recombinant attenuated Salmonella vaccine vectors.Intermittent fasting favored the resolution of Salmonella typhimurium infection in middle-aged BALB/c miceU-Omp19 from Brucella abortus Is a Useful Adjuvant for Vaccine Formulations against Salmonella Infection in MiceIdentification of Protective Antigens for Vaccination against Systemic Salmonellosis.Animal Models for Salmonellosis: Applications in Vaccine ResearchVaccination against Salmonella Infection: the Mucosal Way.Recombinant attenuated Salmonella Typhimurium with heterologous expression of the Salmonella Choleraesuis O-polysaccharide: high immunogenicity and protection.Immunogenicity and efficacy following sequential parenterally-administered doses of Salmonella Enteritidis COPS:FliC glycoconjugates in infant and adult mice.
P2860
Q30415132-1D80B7FA-FA49-4919-BF5F-3E99824013BDQ33788711-AD54668E-ACAE-48C4-A4C7-667BA8654499Q34429033-2CAE555A-4270-4F38-972B-857816DF12C2Q34709684-90DDB397-341C-4ED5-8F92-DEC0B778A236Q34760675-4E216845-DFE6-4849-9F35-3B7E718CEE5AQ34874212-04F1A7C2-746D-41B5-A21A-99E42DD2A6A7Q35186131-A887F561-8E76-4B52-B7AD-DB943F982688Q35272921-D2B7B3B0-01CD-4277-8CAE-C62E53255C8BQ35882563-FADA81CE-C419-4B78-B1B9-A3EA5E456977Q35896237-187ED6C6-BC9C-4DD6-943C-C9281CE05979Q35964671-A50B1CB7-5DFE-4992-96A5-863ED107DD93Q36107133-E10D00C7-0E1E-457A-86B4-A52619CFB174Q36143656-8F1B40B3-8217-4C32-9299-93CB72D150A5Q36281257-C17291F0-C2BE-4E26-8A16-57CB6A9F0BB5Q36653379-40394FCF-7B99-4E5D-B7B6-7E049539D923Q37219548-94B8CBE0-675F-421D-AACD-D8B9871B8859Q37647549-7D467CAF-F765-4E80-BF9F-C2404691CB4BQ38243324-C2C1E6DE-1FE9-4B95-8026-34C11903BECDQ38896014-C45D009F-D22A-493D-9AED-53CD9A3CAFFDQ39373957-E040A85C-44A5-4EC0-A6DE-933CCF1D012DQ40114957-02C2B7D1-1D02-43C6-8DBA-A569326E8DF7Q54201279-5C51C7F0-00CD-44B3-B659-EE2A60A942C6
P2860
Mouse models to assess the efficacy of non-typhoidal Salmonella vaccines: revisiting the role of host innate susceptibility and routes of challenge.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 25 May 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Mouse models to assess the eff ...... ility and routes of challenge.
@en
Mouse models to assess the eff ...... ility and routes of challenge.
@nl
type
label
Mouse models to assess the eff ...... ility and routes of challenge.
@en
Mouse models to assess the eff ...... ility and routes of challenge.
@nl
prefLabel
Mouse models to assess the eff ...... ility and routes of challenge.
@en
Mouse models to assess the eff ...... ility and routes of challenge.
@nl
P2093
P2860
P1433
P1476
Mouse models to assess the eff ...... ility and routes of challenge.
@en
P2093
James E Galen
Raphael Simon
Sharon M Tennant
P2860
P304
P356
10.1016/J.VACCINE.2011.05.022
P407
P577
2011-05-25T00:00:00Z